Abbott Labs (ABT) PT Raised to $145 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
Go back to Abbott Labs (ABT) PT Raised to $145 at Jefferies
October 21, 2021 7:21 AM EDT
Raymond James analyst Jayson Bedford raised the price target on Abbott Labs (NYSE: ABT) to $134.00 (from $128.00) while maintaining a Outperform rating.... More
October 21, 2021 5:43 AM EDT
Citi analyst Joanna Wuensch raised the price target on Abbott Labs (NYSE: ABT) to $141.00 (from $140.00) while maintaining a Buy rating.... More
October 21, 2021 4:36 AM EDT
Morgan Stanley analyst Cecilia Furlong raised the price target on Abbott Labs (NYSE: ABT) to $146.00 (from $136.00) while maintaining a Overweight rating.... More
October 20, 2021 2:27 PM EDT
BTIG analyst Marie Thibault raised the price target on Abbott Labs (NYSE: ABT) to $143.00 (from $136.00) while maintaining a Buy rating.
...
More
October 20, 2021 7:36 AM EDT
By Mrinalika Roy and Carl O'Donnell
(Reuters) - Abbott Laboratories said demand for its COVID-19 tests, especially rapid testing, rebounded as the U.S. wrestled with surging coronavirus cases during the quarter, prompting the company to raise its earnings forecast for the year.
The medical device maker's shares rose 3.5% to $123.53 on Wednesday after it also reported third-quarter earnings above analysts' estimates.
The company said it shipped more than 225 million COVID-19 tests globally in... More
October 20, 2021 7:32 AM EDT
Abbott (NYSE: ABT) reported Q3 EPS of $1.40, $0.47 better than the analyst estimate of $0.93. Revenue for the quarter came in at $10.9 billion versus the consensus estimate of $9.44 billion.
GUIDANCE:
Abbott sees FY2021 EPS of $5.00-$5.10, versus the consensus of $4.45.
For earnings history and earnings-related data on Abbott (ABT) click here.
...
More
